0.1825
-0.0026
(-1.40%)
As of 2:33:52 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Harout Semerjian | CEO & President | 1.1M | -- | 1970 |
| Mr. Brian M. Hahn | Senior VP & CFO | 728.55k | -- | 1974 |
| Ms. Stephanie R. Irish CPA | Vice President of Accounting | -- | -- | 1971 |
| Mr. Christian B. Dinneen-Long | General Counsel & Company Secretary | -- | -- | -- |
| Mr. Bruce Johnson | Senior VP & Chief Commercial Officer | -- | -- | 1968 |
| Mr. Chinmaya Rath | Senior VP & Chief Business Officer | -- | -- | 1977 |
| Mr. Shantha Tyavanagimatt Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
GlycoMimetics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
Corporate Governance
GlycoMimetics, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 9; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
GlycoMimetics, Inc. Earnings Date
Recent Events
April 3, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Related Tickers
SYRE Spyre Therapeutics, Inc.
12.87
-8.01%
LYRA Lyra Therapeutics, Inc.
0.1141
+2.73%
ATXS Astria Therapeutics, Inc.
4.6300
-10.10%
SPRB Spruce Biosciences, Inc.
0.2900
-0.92%
MNOV MediciNova, Inc.
1.2599
-5.98%
PMVP PMV Pharmaceuticals, Inc.
0.9376
-5.77%
ORKA Oruka Therapeutics, Inc.
7.93
-11.10%
GLUE Monte Rosa Therapeutics, Inc.
3.7150
-4.50%
DNTH Dianthus Therapeutics, Inc.
15.65
-7.78%
AVTX Avalo Therapeutics, Inc.
5.68
-13.81%